Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 990-996

  Sepers, Marja D ^a   Raymond, Lynn A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; ENDOCANNABINOID; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

BASAL GANGLION; CORPUS STRIATUM; EXCITOTOXICITY; GENETIC TRANSCRIPTION; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROPATHY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; SYNAPTIC DYSFUNCTION; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYNAPSE;

ANIMALS; CORPUS STRIATUM; DOPAMINE; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 84903781511     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.02.006     Document Type: Review

References (78)

1. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
2. J. Paulsen et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study J. Neurol. Neurosurg. Psychiatry 79 2008 874 880
3. E. Aylward et al. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases Biol. Psychiatry 71 2012 822 828
4. K.M. Biglan et al. Refining the diagnosis of Huntington disease: the PREDICT-HD study Front. Aging Neurosci. 5 2013 12
5. C.A. Ross, and S.J. Tabrizi Huntington's disease: from molecular pathogenesis to clinical treatment Lancet Neurol. 10 2011 83 98
6. L.A. Raymond et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function Neuroscience 198 2011 252 273
7. J. Nasir et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes Cell 81 1995 811 823
8. M. Arrasate, and S. Finkbeiner Protein aggregates in Huntington's disease Exp. Neurol. 238 2012 1 11
9. J.P. Vonsattel, and M. DiFiglia Huntington disease J. Neuropathol. Exp. Neurol. 57 1998 369 384 (Pubitemid 28237321)
10. J.D. Lenz, and M.K. Lobo Optogenetic insights into striatal function and behavior Behav. Brain Res. 2013 10.1016/j.bbr.2013.04.018
11. B. Miller et al. Dysregulated neuronal activity patterns implicate corticostriatal circuit dysfunction in multiple rodent models of Huntington's disease Front. Syst. Neurosci. 5 2010 26
12. D.M. Cummings et al. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease ASN Neuro. 2 2010 e00036
13. D. Eidelberg, and D.J. Surmeier Brain networks in Huntington disease J. Clin. Invest. 121 2011 484 492
14. A.H. Gittis, and A.C. Kreitzer Striatal microcircuitry and movement disorders Trends Neurosci. 35 2012 557 564
15. T.S. Gertler et al. Dichotomous anatomical properties of adult striatal medium spiny neurons J. Neurosci. 28 2008 10814 10824
16. L.-H. Tai et al. Transient stimulation of distinct subpopulations of striatal neurons mimics changes in action value Nat. Neurosci. 15 2012 1281 1289
17. S. Threlfell et al. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons Neuron 75 2012 58 64
18. C. Cepeda et al. Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models J. Neurosci. 33 2013 7393 7406
19. N. Tritsch et al. Dopaminergic neurons inhibit striatal output through non-canonical release of GABA Nature 490 2012 262 266
20. V.M. André et al. Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease Front. Syst. Neurosci. 5 2011 46
21. C.R. Gerfen, and D.J. Surmeier Modulation of striatal projection systems by dopamine Annu. Rev. Neurosci. 34 2011 441 466
22. L.H. Poon et al. Role of tetrabenazine for Huntington's disease-associated chorea Ann. Pharmacother. 44 2010 1080 1089
23. C. Cepeda et al. Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms ASN Neuro. 2 2009 e00033
24. V. André et al. Differential electrophysiological changes in striatal output neurons in Huntington's disease J. Neurosci. 31 2011 1170 1182
25. D. Charvin et al. Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo Neurobiol. Dis. 29 2007 22 29 (Pubitemid 350182435)
26. B.R. Miller et al. Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease J. Neurochem. 121 2012 629 638
27. A.M. Estrada-Sánchez, and G.V. Rebec Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes Basal Ganglia 2 2012 57 66
28. M. Faideau et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects Hum. Mol. Genet. 19 2010 3053 3067
29. J. Bradford et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms Proc. Natl. Acad. Sci. U. S. A. 106 2009 22480 22485
30. C. Corti et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection J. Neurosci. 27 2007 8297 8308 (Pubitemid 47219630)
31. A. Reiner et al. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice Neurobiol. Dis. 47 2012 75 91
32. M. Beal et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid Nature 321 1985 168 171
33. S.T. Lee et al. Memantine reduces striatal cell death with decreasing calpain levelin 3-nitropropionic model of Huntington's disease Brain Res. 1118 2006 199 207
34. R. Graham et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease J. Neurosci. 29 2009 2193-2120
35. O. Hansson et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene Eur. J. Neurosci. 14 2001 1492 1504 (Pubitemid 35463716)
36. A. Milnerwood, and L. Raymond Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load J. Physiol. 585 2007 817 831
37. A. Milnerwood et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice Neuron 65 2010 178 190
38. P. Joshi et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease J. Neurosci. 29 2009 2414 2427
39. P. Paoletti et al. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease Nat. Rev. Neurosci. 14 2013 383 400
40. M. Rigby et al. The messenger RNAs for the N-methyl-d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain Neuroscience 73 1996 429 447 (Pubitemid 26168802)
41. Y. Liu et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo J. Neurosci. 27 2007 2846 2857 (Pubitemid 46438991)
42. M.-A. Martel et al. The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults Neuron 74 2012 543 556
43. B. Lujan et al. Differential roles of GluN2A- and GluN2B-containing NMDA receptors in neuronal survival and death Int. J. Physiol. Pathophysiol. Pharmacol. 4 2011 211 218
44. M. Fan et al. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease J. Neurosci. 27 2007 3768 3779 (Pubitemid 46557661)
45. 2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease Neurobiol. Dis. 31 2008 80 88
46. M.Y. Heng et al. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease J. Neurosci. 29 2009 3200 3205
47. E.L. Jocoy et al. Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-d-aspartate currents by dopamine D1 receptor activation in striatum Front. Syst. Neurosci. 5 2011 28
48. G.E. Hardingham, and H. Bading Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders Nat. Rev. Neurosci. 11 2010 682 696
49. S. Okamoto et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin Nat. Med. 15 2009 1407 1413
50. A.J. Milnerwood et al. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice Neurobiol. Dis. 48 2012 40 51
51. S.A. Lipton Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond Nat. Rev. Drug Discov. 5 2006 160 170
52. W.G. Ondo et al. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease Parkinsonism Relat. Disord. 13 2007 453 454 (Pubitemid 47446371)
53. C. Ikonomidou, and L. Turski Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 1 2002 383 386 (Pubitemid 37159164)
54. B. Lu et al. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases Nat. Rev. Neurosci. 14 2013 401 416
55. Y. Li et al. Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development Proc. Natl. Acad. Sci. U. S. A. 109 2012 15491 15496
56. L.R. Gauthier et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules Cell 118 2004 127 138 (Pubitemid 38902819)
57. Y. Xie et al. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice J. Neurosci. 30 2010 14708 14718
58. C. Zuccato et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease Physiol. Rev. 90 2010 905 981
59. G. Liot et al. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites J. Neurosci. 33 2013 6298 6309
60. S. Ginés et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain Eur. J. Neurosci. 23 2006 649 658
61. P. Samadi et al. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease Genes Brain Behav. 12 2013 108 124
62. A. Giralt et al. Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction Mol. Neurodegener. 6 2011 71
63. K. Gharami et al. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice J. Neurochem. 105 2008 369 379 (Pubitemid 351490006)
64. M. Jiang et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease Hum. Mol. Genet. 22 2013 2462 2470
65. D.A. Simmons et al. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice Neurobiol. Dis. 41 2011 436 444
66. G. Lynch et al. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease J. Neurosci. 27 2007 4424 4434 (Pubitemid 46640726)
67. Y. Jia et al. Presynaptic BDNF promotes postsynaptic long-term potentiation in the dorsal striatum J. Neurosci. 30 2010 14440 14445
68. M. Navarrete, and A. Araque Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes Neuron 68 2010 113 126
69. i receptors regulate neuronal energy metabolism Nat. Neurosci. 15 2012 558 564
70. J. Fernández-Ruiz et al. Prospects for cannabinoid therapies in basal ganglia disorders Br. J. Pharmacol. 163 2011 1365 1378
71. A. Curtis et al. A pilot study using nabilone for symptomatic treatment in Huntington's disease Mov. Disord. 24 2009 2254 2259
72. M. Glass et al. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease Neuroscience 97 2000 505 519 (Pubitemid 30320757)
73. K. Van Laere et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo J. Nucl. Med. 51 2010 1413 1417
74. V. Chiodi et al. Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease Neurobiol. Dis. 45 2012 983 991
75. E.A. Horne et al. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models Eur. J. Neurosci. 37 2013 429 440
76. I. Lastres-Becker et al. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate NeuroReport 14 2003 813 816 (Pubitemid 36667917)
77. C. Blázquez et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease Brain 134 2011 119 136
78. V. Micale et al. Endocannabinoid system and mood disorders: priming a target for new therapies Pharmacol. Ther. 138 2013 18 37